“Only buy something that you’d be perfectly happy to hold if the market shut down for 10 years.”
— Warren Buffett
The investment philosophy practiced by Warren Buffett calls for investors to take a long-term horizon when making an investment, such as a ten year holding period (or even longer), and reconsider making the investment in the first place if unable to envision holding the stock for at least five years. In that spirit, examining how a single name performs over a full market cycle can provide useful perspective on both return potential and risk tolerance.
IQVIA Holdings Inc ( NYSE: IQV ), a leading provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been one such long-term compounder. The company in its present form was created in 2016 through the merger of IMS Health and Quintiles, and today sits at the center of pharmaceutical and biotechnology R&D, commercialization, and real-world evidence generation.
Below we consider how a long-term buy-and-hold strategy fared for an investor who committed 10,000 dollars to IQVIA on April 4, 2016 and simply held that position through April 1, 2026, with no additional contributions or withdrawals and assuming no dividends were paid.
| Start date: | 04/04/2016 |
|
|||
| End date: | 04/01/2026 | ||||
| Start price/share: | $68.42 | ||||
| End price/share: | $172.40 | ||||
| Starting shares: | 146.16 | ||||
| Ending shares: | 146.16 | ||||
| Dividends reinvested/share: | $0.00 | ||||
| Total return: | 151.97% | ||||
| Average annual return: | 9.68% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $25,186.31 | ||||
As we can see, the ten year investment result worked out well, with an annualized rate of return of 9.68%. This would have turned a 10,000 dollar investment made 10 years ago into $25,186.31 today (as of 04/01/2026). On a total return basis, that is a gain of 151.97% based solely on price appreciation, as IQVIA has not historically paid a regular cash dividend. For context, a broadly diversified U.S. equity portfolio over similar long periods has often compounded in the mid- to high-single-digit range, so IQVIA’s performance would have been broadly competitive with the wider market despite periods of volatility.
It is also worth noting that investors over this span navigated several significant macro and sector-specific events, including shifting interest-rate expectations, changing regulatory and reimbursement environments in healthcare, and the global COVID-19 pandemic, which simultaneously created operational challenges and heightened the importance of data-driven clinical development and real-world evidence. IQVIA’s role as an outsourced partner to large pharmaceutical and biotechnology companies, and its extensive data assets and analytics capabilities, have helped support long-term revenue and earnings growth through these cycles.
Looking ahead, the same long-term framework applies. Structural drivers such as an aging global population, increased prevalence of chronic diseases, rising complexity and cost of clinical trials, and the growing use of artificial intelligence and machine learning within healthcare data analytics could continue to underpin demand for IQVIA’s services. At the same time, prospective investors should remain mindful of valuation, execution risk, and regulatory scrutiny around the use of healthcare data.
As always, past performance does not guarantee future results, and a backward-looking 10-year snapshot cannot substitute for a thorough assessment of a company’s balance sheet, competitive positioning, and strategy. However, this case study underlines the power of patience and the compounding effect described by Warren Buffett: committing capital to a high-quality business and holding through cycles can materially increase portfolio value over time. Something to consider is how IQV shares might perform over the next 10 years in light of those same structural trends.
[These numbers were computed with the Dividend Channel DRIP Returns Calculator.]
For investors considering similar long-duration holdings, disciplined portfolio construction, ongoing fundamental monitoring and an understanding of individual risk tolerance remain critical. Long-term case studies such as IQVIA’s can be a useful input to that process, but should be combined with independent research and, where appropriate, professional advice.
Here’s one more great investment quote before you go:
“As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
